Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.
Vaccine X
; 11: 100165, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1814868
ABSTRACT
Little is known about the factors associated with lack of T-cell response to mRNA vaccines against SARS-CoV-2. In a prospective cohort of 61 health care workers (HCWs), 21% and 16% after the first dose of mRNA BNT162b vaccine, and 12% and 7% after the second dose, showed lack of CD4+ and CD8+ T-cell response, respectively. Pre-existing T-cell immunity, due to past infection (46%) or cross-reactive cellular response (26%), was significantly associated with T-cell response in frequency (CD4+ T-cell, 100% vs 82% after two doses; p = 0.049) and in the magnitude of T-cell response during follow up. Furthermore, baseline CD4+ T-cell correlated positively with the titer of specific IgG-antibodies after first and second vaccine dose. Our data demonstrate that cross-reactive T-cells correlate with a better cellular response as well as an enhanced humoral response, and we confirm the close correlation of humoral and cellular response after mRNA vaccination.
AU, arbitrary units; CLIA, chemoluminiscent immunoassay; COVID-19, Coronavirus disease 2019; Cellular response; IgG, immunoglobulin G; Pre-existing immunity; RT-PCR, retrotranscriptasepolymerase chain reaction; S protein, Spike protein; SARS-CoV-2 humoral response; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; mRNA vaccine
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Language:
English
Journal:
Vaccine X
Year:
2022
Document Type:
Article
Affiliation country:
J.jvacx.2022.100165
Similar
MEDLINE
...
LILACS
LIS